Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise

Tiger Newspress03-31 19:00

Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions.

The Cambridge, Massachusetts-based biotech company will pay $41 a share for Apellis, or more than double the company’s closing price on Monday. Apellis’ stock has declined 32% so far this year.

Apellis shares soared 137.6% in pre-market trading. Biogen shares were down about 1%.

Biogen will gain two approved drugs in the deal. Apellis’ best-selling medicine is Syfovre, which treats an immune disorder that’s a leading cause of blindness. It generated $587 million in revenue last year. The other, Empaveli, treats both a blood disorder and rare kidney diseases, the latter of which has become an area of focus for Biogen. Last year, Empaveli generated more than $100 million in sales.

Biogen Chief Executive Officer Chris Viehbacher has been trying to find new sources of growth as the company’s aging multiple sclerosis franchise declines and its Alzheimer’s treatment gets off to a slow start.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1167344429?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1167344429","market":"us","top_or_hot":-1,"title":"Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise","media":"Tiger Newspress","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/BIIB\">Biogen</a> has agreed to acquire <a href=\"https://laohu8.com/S/APLS\">Apellis Pharmaceuticals</a> for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions.</p><p style=\"text-align: start;\">The Cambridge, Massachusetts-based biotech company will pay $41 a share for Apellis, or more than double the company’s closing price on Monday.<strong> </strong>Apellis’ stock has declined 32% so far this year.</p><p style=\"text-align: start;\">Apellis shares soared 137.6% in pre-market trading. Biogen shares were down about 1%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/bfeb54dd86f6097ecff77f66e61dd2b6\" tg-width=\"534\" tg-height=\"149\"/></p><p style=\"text-align: start;\">Biogen will gain two approved drugs in the deal. Apellis’ best-selling medicine is Syfovre,<strong> </strong>which treats an immune disorder that’s a leading cause of blindness. It generated $587 million in revenue last year. The other, Empaveli, treats both a blood disorder and rare kidney diseases, the latter of which has become an area of focus for Biogen. Last year, Empaveli generated more than $100 million in sales.</p><p style=\"text-align: start;\">Biogen Chief Executive Officer Chris Viehbacher has been trying to find new sources of growth as the company’s aging multiple<em> </em>sclerosis franchise declines and its Alzheimer’s treatment gets off to a slow start.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2026-03-31 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/BIIB\">Biogen</a> has agreed to acquire <a href=\"https://laohu8.com/S/APLS\">Apellis Pharmaceuticals</a> for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions.</p><p style=\"text-align: start;\">The Cambridge, Massachusetts-based biotech company will pay $41 a share for Apellis, or more than double the company’s closing price on Monday.<strong> </strong>Apellis’ stock has declined 32% so far this year.</p><p style=\"text-align: start;\">Apellis shares soared 137.6% in pre-market trading. Biogen shares were down about 1%.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/bfeb54dd86f6097ecff77f66e61dd2b6\" tg-width=\"534\" tg-height=\"149\"/></p><p style=\"text-align: start;\">Biogen will gain two approved drugs in the deal. Apellis’ best-selling medicine is Syfovre,<strong> </strong>which treats an immune disorder that’s a leading cause of blindness. It generated $587 million in revenue last year. The other, Empaveli, treats both a blood disorder and rare kidney diseases, the latter of which has become an area of focus for Biogen. Last year, Empaveli generated more than $100 million in sales.</p><p style=\"text-align: start;\">Biogen Chief Executive Officer Chris Viehbacher has been trying to find new sources of growth as the company’s aging multiple<em> </em>sclerosis franchise declines and its Alzheimer’s treatment gets off to a slow start.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APLS","symbol_name":"Apellis Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1167344429","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1167344429","pubTimestamp":1774954829,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APLS":"Apellis Pharmaceuticals Inc.","BIIB":"渤健公司"},"translate_title":"百健(Biogen)将以56亿美元收购Apellis以增强肾脏专营权","themeId":"b2495f52240e7e9378faffff6c56a404","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/3ce4379dad6975f1f262569d787845f2","symbols_score_info":{"APLS":2,"BIIB":2},"content_text":"Biogen has agreed to acquire Apellis Pharmaceuticals for $5.6 billion, expanding its treatments in immunology and rare diseases in one of the company’s largest-ever acquisitions.The Cambridge, Massachusetts-based biotech company will pay $41 a share for Apellis, or more than double the company’s closing price on Monday. Apellis’ stock has declined 32% so far this year.Apellis shares soared 137.6% in pre-market trading. Biogen shares were down about 1%.Biogen will gain two approved drugs in the deal. Apellis’ best-selling medicine is Syfovre, which treats an immune disorder that’s a leading cause of blindness. It generated $587 million in revenue last year. The other, Empaveli, treats both a blood disorder and rare kidney diseases, the latter of which has become an area of focus for Biogen. Last year, Empaveli generated more than $100 million in sales.Biogen Chief Executive Officer Chris Viehbacher has been trying to find new sources of growth as the company’s aging multiple sclerosis franchise declines and its Alzheimer’s treatment gets off to a slow start.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1167344429","isCrawlerRequest":true}